Enzo Biochem, Inc. (ENZ)

$1.11 -2.63% $-0.03 Healthcare

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing ‘STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.

$57.12M

Mr. Hamid Erfanian

465.00

New York, NY

Jun 13, 1980

-3.17

$-0.35

2.87

3.50

76.62%

947.53%

1.31

-0.00

0.85

12.43

3.16

47.86%

61.16%

Similar stocks (9)

Sotera Health Company

SHC

$16.60 0.27%
Uptrend

Castle Biosciences, Inc.

CSTL

$30.98 1.47%
Uptrend

Biodesix, Inc.

BDSX

$1.80 0.84%
Uptrend

Sera Prognostics, Inc.

SERA

$7.71 -1.15%
Neutral

FONAR Corporation

FONR

$17.49 0.52%
Downtrend

Exagen Inc.

XGN

$2.90 1.64%
Uptrend

DarioHealth Corp.

DRIO

$0.97 -2.00%
Downtrend

Neuronetics, Inc.

STIM

$0.93 -1.84%
Downtrend

Psychemedics Corporation

PMD

$2.31 -0.86%
Downtrend

ETF Exposure (13)

iShares Micro-Cap ETF

IWC

0.01284%

$125.19 -1.07%
Uptrend

Dimensional U.S. Targeted Value ETF

DFAT

9.051399999999999e-4%

$55.32 -1.06%
Uptrend

Dimensional U.S. Core Equity 2 ETF

DFAC

2.2032e-4%

$33.92 -0.64%
Uptrend

Vanguard Balanced Index Fund Institutional Shares

VBAIX

0%

$49.96 1.07%
Uptrend

Vanguard Balanced Index Fund Admiral Shares

VBIAX

0%

$49.95 1.07%
Uptrend

Vanguard Balanced Index Fund

VBINX

0%

$49.94 1.05%
Uptrend

Vanguard Extended Market Index Fund Institutional Shares

VIEIX

0%

$138.77 2.02%
Uptrend

Vanguard Institutional Total Stock Market Index Fund Institutional Shares

VITNX

0%

$97.80 1.74%
Uptrend

Vanguard Institutional Total Stock Market Index Fund

VITPX

0%

$97.78 1.74%
Uptrend

Vanguard Total Stock Market Index Fund

VITSX

0%

$137.33 1.73%
Uptrend

Vanguard Total Stock Market Index Fund

VTI

0%

$280.66 -0.49%
Uptrend

Vanguard Total Stock Market Index Fund

VTSAX

0%

$137.30 1.73%
Uptrend

Vanguard Extended Market Index Fund

VXF

0%

$181.47 -0.79%
Uptrend